Terns Pharma, a Shanghai-San Francisco biopharma, reported TERN-101, a potential treatment for NASH, was well tolerated and seemed to engage its FXR target in a US Phase I trial. The trial was a randomized, double-blind, placebo-controlled study designed to evaluate safety, pharmacokinetics, pharmacodynamics and plasma biomarkers of FXR pathway activation. It enrolled 36 healthy participants who received placebo or TERN-101 at various dose levels for seven days. Terns said biomarker studies showed reductions in levels that imply efficacy in treating liver fibrosis. More details....
Share this with colleagues:
Original Article: Terns Announces Positive Data from Phase I Trial of NASH Candidate